secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2021-10-06T23:59:59+00:00
Accession:  0001193125-21-292589
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gemini Therapeutics restructures, cuts 20% of workforce, focuses on GEM103 pivotal trial for GA
--------------------------------------------------------------------------------

- Workforce cut by 20% (11 positions); pre-tax restructuring charge of $1.3M–$1.6M in Q4 2021.
- CMO Samuel Barone retains title but no longer oversees regulatory/medical; Avner Ingerman promoted to CDO; Barone eligible for $100K bonus and retention pay.
- Chief Scientific Officer (Walter Strapps) and Chief People Officer (Precillia Redmond) roles eliminated by year-end 2021.
- Company shifts to development-stage, ceasing research programs to focus on GEM103 pivotal trial in GA planned for early 2022.
- CFO Brian Piekos adds Chief Business Officer role; Chair Georges Gemayel becomes Executive Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/0001193125-21-292589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312521292589/d213931d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-292589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer